262 related articles for article (PubMed ID: 22017180)
1. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
2. Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
Węsierska-Gądek J; Mauritz M
Future Med Chem; 2016 Jan; 8(1):55-72. PubMed ID: 26692095
[TBL] [Abstract][Full Text] [Related]
3. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
4. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akin S; Babacan T; Sarici F; Altundag K
J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
[TBL] [Abstract][Full Text] [Related]
5. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
6. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Wesierska-Gadek J; Borza A; Komina O; Maurer M
Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
Cariou S; Donovan JC; Flanagan WM; Milic A; Bhattacharya N; Slingerland JM
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9042-6. PubMed ID: 10908655
[TBL] [Abstract][Full Text] [Related]
8. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
10. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
11. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
12. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells.
Cover CM; Hsieh SJ; Cram EJ; Hong C; Riby JE; Bjeldanes LF; Firestone GL
Cancer Res; 1999 Mar; 59(6):1244-51. PubMed ID: 10096555
[TBL] [Abstract][Full Text] [Related]
13. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
16. DDT mimicks estradiol stimulation of breast cancer cells to enter the cell cycle.
Dees C; Askari M; Foster JS; Ahamed S; Wimalasena J
Mol Carcinog; 1997 Feb; 18(2):107-14. PubMed ID: 9049186
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the cell cycle in cancer.
Sandhu C; Slingerland J
Cancer Detect Prev; 2000; 24(2):107-18. PubMed ID: 10917130
[TBL] [Abstract][Full Text] [Related]
18. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
Iavarone A; Massagué J
Nature; 1997 May; 387(6631):417-22. PubMed ID: 9163429
[TBL] [Abstract][Full Text] [Related]
19. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
20. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Ohmori T; Yang JL; Price JO; Arteaga CL
Exp Cell Res; 1998 Dec; 245(2):350-9. PubMed ID: 9851876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
